Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 14/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18707129 | 0.82 | HRH3 (0.59) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL21334459 | 0.82 | HRH3 (0.59) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL31081530 | 0.82 | HRH3 (0.59) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL22885894 | 0.82 | HRH3 (0.59) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL18707030 | 0.82 | HRH3 (0.59) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL20524367 | 0.81 | HRH3 (0.58) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL21334989 | 0.78 | HRH3 (0.56) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL21093383 | 0.78 | HRH3 (0.56) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL21093378 | 0.78 | HRH3 (0.56) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL15314509 | 0.77 | HRH3 (1.00) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | HRH3 137/4885HDAC3 2434/4885HDAC4 1245/4885 |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | HRH3 137/4885HDAC3 2434/4885HDAC4 1245/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | HRH3 271/4885HDAC3 1323/4885HDAC4 1358/4885 |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HIPK2, IP6K1 | HRH3 271/4885HDAC3 1323/4885HDAC4 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.